Navigation Links
Wearable Artificial Kidney Passes Test
Date:12/14/2007

8 end-stage kidney failure patients used the device for up to 8 hours, researchers say

FRIDAY, Dec. 14 (HealthDay News) -- The first version of an American-designed wearable artificial kidney has delivered promising results in a pilot trial, British physicians report.

Five men and three women newly diagnosed with end-stage kidney failure used the device for between four and eight hours, according to a report in the Dec. 15 issue of the journal The Lancet.

The device resembles a large tool-belt hung with a variety of devices needed for the dialysis process. Using miniaturized components, it produced satisfactory, if small, rates of blood flow and clearance of toxins from the body, the report said.

That slow rate actually offers an advantage over standard dialysis, said Dr. Garabed Eknoyan, professor of medicine at Baylor College of Medicine, who wrote an accompanying editorial.

Dialysis now is done in three- or four-hour sessions, three times a week, Eknoyan said. "There are two major problems," he said. "The changes occur fast, and removal occurs very fast, before the body gets a chance to accommodate, so there is discomfort with the process. If you dialyse at a lower rate for a longer period, the patient does better."

But dialyzing at a slower rate using a standard artificial kidney has major disadvantages, Eknoyan said. "The patient is tied down to the machine," he said. "Not every patient is willing to cope with that."

The new device was designed by Dr. Victor Gura, a nephrologist at the University of California, Los Angeles. He is chief medical officer of Xcorporeal Inc., the company that made the device.

The discomfort and inefficiency of current dialysis treatment is becoming a bigger issue every years, said Dr. William Henry Fissell, director of the Cleveland Clinic Center for Extracorporeal Therapy.

"The population of patients requiring dialysis has been growing by 8 percent a year for a quarter-century," Fissell said. "The United States now has 400,000 patients on maintenance dialysis."

That increase is due to the growing ability of physicians to prolong the lives of people with the various aliments associated with cardiovascular risk factors such as diabetes and obesity, he said. Kept alive, many of those people will eventually develop kidney failure, Fissell said, and they often find current dialysis therapy unsatisfactory.

An informal network of kidney experts is working to develop better dialysis technology, and the new device is one example of the effort, Fissell said.

Major tests lie ahead, Eknoyan said. "Now that it has passed this stage of trial, we must go to the stage where people use it several times a day," he said. "It remains to be seen how it is going to work. But the evidence is there, and the need is there that people need to dialyze more frequently."

More information

There's more on kidney failure and dialysis at the U.S. National Library of Medicine.



SOURCES: Garabed Eknoyan, M.D., professor, medicine, Baylor College of Medicine, Houston; William Henry Fissell, M.D., director, Cleveland Clinic Center for Extracorporeal Therapy; Dec. 15, 2007 The Lancet


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New Herbal Water Creating Taste Sensation: Ayalas Herbal Water Has No Calories, No Preservatives and No Artificial Additives. Just All the Natural Benefits of Herbs!
2. Brain measurements could lead to better devices to move injured or artificial limbs
3. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
4. Expenses Overshadow Optimism for Kidney Failure Patients
5. Katie Lee Joel to Conduct Cooking Demonstration for Local Patients With Chronic Kidney Disease
6. Experimental drug shows promise in advanced kidney cancer
7. New Kidney Disease Can Be Fatal
8. Lowering Blood Protein Wont Help Kidney Patients
9. DaVita Teammates Bicycling 230 Miles for Kidney Disease Education
10. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
11. Metabolic syndrome heightens risk for development of uric-acid kidney stones
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Wearable Artificial Kidney Passes Test
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located ... training and leads programs. , In February, 2017, Empower Brokerage introduced their new ... Partners is designed to teach how to maximize their sales efforts, as well ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: ... events will interrelate. “End Time GPS” is the creation of published author, Wesley ... while working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
(Date:3/23/2017)... Texas (PRWEB) , ... March 23, 2017 , ... The ... 3rd location in the greater Houston Area. The new location is located at 2255 ... Luke’s Hospital in Springwoods Village. This newest location will provide patients living in the ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Center at 10 North Broadway Avenue, will be an educational and exciting program ... instruction in the management of chronic pain. , Oklahoma is in a healthcare ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets ... the U.S.: Consumer Strategies" report to their offering. ... Pain ... approach and treat their physical pain, emphasizing consumer survey analysis, ... pain sufferers and adults who have selected illnesses/conditions strongly associated ...
(Date:3/24/2017)... , March 24, 2017 ShangPharma, ... high-quality and cost-effective drug development and discovery ... and biotechnology industry, announced today the intent ... ShangPharma will be consolidating the Contract Research ... under Shanghai ChemPartner. These entities include ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology: